FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

M Miller

Research Profile

Chemicals & Drugs

Living Beings

Physiology

Disorders

Anatomy

Co-author Network

Publications

TOP 3
S-C C Sun; K A Wong; X Qi; A Bae; J Harris; M Miller; H Mo
Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.
Andrew S Bae; Karin S Ku; M Miller; Hongmei Mo; Evguenia S Svarovskaia
Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.
H Mo; C Yang; K Wang; Y Wang; M Huang; B Murray; X Qi; S-C Sun; M Deshpande; G Rhodes; M Miller
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of M Miller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: S-C C Sun; K A Wong; X Qi; A Bae; J Harris; M Miller; H Mo
Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.
Journal of viral hepatitis 2011;18(12):861-70.
2011: Andrew S Bae; Karin S Ku; M Miller; Hongmei Mo; Evguenia S Svarovskaia
Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.
Journal of clinical microbiology 2011;49(9):3168-74.
2011: H Mo; C Yang; K Wang; Y Wang; M Huang; B Murray; X Qi; S-C Sun; M Deshpande; G Rhodes; M Miller
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Journal of viral hepatitis 2011;18(5):338-48.
2010: Andrew Bae; Siu-Chi Sun; Xiaoping Qi; Xiaowu Chen; Karin Ku; Angela Worth; Kelly A Wong; Jeanette Harris; M Miller; Hongmei Mo
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
Antimicrobial agents and chemotherapy 2010;54(12):5288-97.
2010: Shaday Michan; Ying Li; Maggie Meng-Hsiu Chou; Edoardo Parrella; Huanying Ge; Jeffrey M Long; Joanne S Allard; Kaitlyn Lewis; M Miller; Wei Xu; Ronald F Mervis; Jing Chen; Karen I Guerin; Lois E H Smith; Michael W McBurney; David A Sinclair; Michel Baudry; Rafael de Cabo; Valter D Longo
SIRT1 is essential for normal cognitive function and synaptic plasticity.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2010;30(29):9695-707.
2010: M Miller
The early years of retroviral protease crystal structures.
Biopolymers 2010;94(4):521-9.
2009: Ronald C Kessler; Guilherme Borges; N Sampson; M Miller; M K Nock
The association between smoking and subsequent suicide-related outcomes in the National Comorbidity Survey panel sample.
Molecular psychiatry 2009;14(12):1132-42.
2009: Kenneth J Mukamal; Christina C Wee; M Miller
BMI and rates of suicide in the United States: an ecological analysis.
Obesity (Silver Spring, Md.) 2009;17(10):1946-50.
2008: Evguenia S Svarovskaia; Joy Y Feng; Nicolas A Margot; Florence Myrick; Derrick Goodman; John K Ly; Kirsten L White; Nilima Kutty; Ruth Wang; Katyna Borroto-Esoda; M Miller
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Journal of acquired immune deficiency syndromes (1999) 2008;48(4):428-36.
2008: Robert J Murray; Fraser I Lewis; M Miller; Andrew J Leigh Brown
Genetic basis of variation in tenofovir drug susceptibility in HIV-1.
AIDS (London, England) 2008;22(10):1113-23.
2008: Bart Winters; Julio Montaner; P Richard Harrigan; Brian Gazzard; Anton Pozniak; M Miller; Sean Emery; Frank van Leth; Patrick Robinson; John D Baxter; Marie Perez-Elias; Delivette Castor; Scott Hammer; Alex Rinehart; Hans Vermeiren; Elke Van Craenenbroeck; Lee Bacheler
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
Journal of acquired immune deficiency syndromes (1999) 2008;48(1):26-34.
2008: Ivona Pandrea; Ruy M Ribeiro; Rajeev Gautam; Thaidra Gaufin; Melissa Pattison; Mary Barnes; Christopher Monjure; Crystal Stoulig; Jason Dufour; Wayne Cyprian; Guido Silvestri; M Miller; Alan S Perelson; Cristian Apetrei
Simian immunodeficiency virus SIVagm dynamics in African green monkeys.
Journal of virology 2008;82(7):3713-24.
2008: Shari N Gordon; Richard Dunham; Jessica Engram; Jacob Estes; Zichun Wang; Nichole R Klatt; Mirko Paiardini; Ivona Pandrea; Cristian Apetrei; Donald L Sodora; Ha Youn Lee; Ashley T Haase; M Miller; Amitinder Kaur; Silvija I Staprans; Alan S Perelson; Mark B Feinberg; Guido Silvestri
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis.
Journal of virology 2008;82(7):3725-35.
2008: Jennifer E Vela; M Miller; Gerald R Rhodes; Adrian S Ray
Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.
Antiviral therapy 2008;13(6):789-97.
2008: Damian J McColl; Colombe Chappey; Neil T Parkin; M Miller
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
Antiviral therapy 2008;13(2):189-97.
2007: M Miller
Resistance to integrase inhibitors.
Journal of HIV therapy 2007;12(4):101.
2007: Katyna Borroto-Esoda; M Miller; Sarah Arterburn
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.
Journal of hepatology 2007;47(4):492-8.
2007: Yuao Zhu; Maria Curtis; Andrea Snow-Lampart; Huiling Yang; William Delaney; M Miller; Katyna Borroto-Esoda
In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations.
Journal of clinical microbiology 2007;45(10):3335-41.
2007: Evguenia S Svarovskaia; Nicolas A Margot; Andrew S Bae; Joshua M Waters; Derrick Goodman; Lijie Zhong; Katyna Borroto-Esoda; M Miller
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):174-80.
2007: Stephanie Dominguez; Jade Ghosn; Gilles Peytavin; Hassane Izzedine; Marc Wirden; Nadine Ktorza; M Miller; Camille Aubron-Olivier; Aldo Trylesinski; Vincent Calvez; Gilbert Deray; Christine Katlama
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Journal of medical virology 2007;79(2):105-10.
2007: John K Ly; Nicolas A Margot; Holly L MacArthur; Magdeleine Hung; M Miller; Kirsten L White
The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
Antiviral chemistry & chemotherapy 2007;18(6):307-16.
2007: Katyna Borroto-Esoda; Neil Parkin; M Miller
A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Antiviral chemistry & chemotherapy 2007;18(5):297-300.
2007: Xiaoping Qi; Shelly Xiong; Huiling Yang; M Miller; William E Delaney
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Antiviral therapy 2007;12(3):355-62.
2006: Nicolas A Margot; Joshua M Waters; M Miller
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Antimicrobial agents and chemotherapy 2006;50(12):4087-95.
2006: Evguenia S Svarovskaia; Michael J Moser; Andrew S Bae; James R Prudent; M Miller; Katyna Borroto-Esoda
MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.
Journal of clinical microbiology 2006;44(11):4237-41.
2006: William E Delaney; Adrian S Ray; Huiling Yang; Xiaoping Qi; Shelly Xiong; Yuao Zhu; M Miller
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
Antimicrobial agents and chemotherapy 2006;50(7):2471-7.
2006: Katyna Borroto-Esoda; Jennifer E Vela; Florence Myrick; Adrian S Ray; M Miller
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Antiviral therapy 2006;11(3):377-84.
2005: Christophe Delaunay; Françoise Brun-Vézinet; Roland Landman; Gilles Collin; Gilles Peytavin; Aldo Trylesinski; Philippe Flandre; M Miller; Diane Descamps
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Journal of virology 2005;79(15):9572-8.
2005: Diane V Havlir; Kersten K Koelsch; Matthew C Strain; Nicolas Margot; Biao Lu; Caroline C Ignacio; M Miller; Joseph Wong
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
The Journal of infectious diseases 2005;191(7):1164-8.
2005: Jan Weber; Bikram Chakraborty; Jitka Weberova; M Miller; Miguel E Quiñones-Mateu
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.
Journal of clinical microbiology 2005;43(3):1395-400.
2005: Huiling Yang; Xiaoping Qi; Alex Sabogal; M Miller; Shelly Xiong; William E Delaney
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.
Antiviral therapy 2005;10(5):625-33.
2005: Adrian S Ray; Florence Myrick; Jennifer E Vela; Loren Y Olson; Eugene J Eisenberg; Katyna Borroto-Esodo; M Miller; Arnold Fridland
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Antiviral therapy 2005;10(3):451-7.
2005: Nicolas A Margot; M Miller
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Antiviral therapy 2005;10(2):343-8.
2004: Ling Shen; Yun Shen; Dan Huang; Liyou Qiu; Prabhat Sehgal; George Z Du; M Miller; Norman L Letvin; Zheng W Chen
Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
The Journal of infectious diseases 2004;190(8):1438-47.
2004: Françoise Brun-Vézinet; Dominique Costagliola; Mounir Ait Khaled; Vincent Calvez; François Clavel; Bonaventura Clotet; Richard Haubrich; Dale J Kempf; Marty King; Daniel R Kuritzkes; Randall Lanier; M Miller; Veronica Miller; Andrews Phillips; Deenan Pillay; Jonathan M Schapiro; Janna Scott; Robert Shafer; Maurizio Zazzi; Andrew R Zolopa; Victor DeGruttola
Clinically validated genotype analysis: guiding principles and statistical concerns.
Antiviral therapy 2004;9(4):465-78.
2004: Bernard Masquelier; Catherine Tamalet; Brigitte Montès; Diane Descamps; Gilles Peytavin; Laurence Bocket; Marc Wirden; Jacques Izopet; Véronique Schneider; Virginie Ferré; Annick Ruffault; Pierre Palmer; Aldo Trylesinski; M Miller; Françoise Brun-Vézinet; Dominique Costagliola
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Antiviral therapy 2004;9(3):315-23.
2004: Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija I Staprans; M Miller; Koen K A Van Rompay; Eric L Delwart
Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.
Journal of virology 2004;78(5):2434-44.
2004: Jérôme Deval; Kirsten L White; M Miller; Neil T Parkin; Jérôme Courcambeck; Philippe Halfon; Boulbaba Selmi; Joëlle Boretto; Bruno Canard
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.
The Journal of biological chemistry 2004;279(1):509-16.
2003: Christopher E Westland; William E Delaney; Huiling Yang; Shan-Shan Chen; Patrick Marcellin; Stephanos Hadziyannis; Robert Gish; John Fry; Carol L Brosgart; Craig Gibbs; M Miller; Shelly Xiong
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.
Gastroenterology 2003;125(1):107-16.
2003: Damian J McColl; M Miller
The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1.
The Journal of antimicrobial chemotherapy 2003;51(2):219-23.
2002: P Richard Harrigan; M Miller; Paula McKenna; Zabrina L Brumme; Brendan Larder
Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 2002;46(4):1067-72.
2001: Yun Shen; Ling Shen; Prabhat Sehgal; Dejiang Zhou; Meredith Simon; M Miller; E A Enimi; B Henckler; L Chalifoux; N Sehgal; M Gastron; Norman L Letvin; Zheng W Chen
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Journal of virology 2001;75(18):8690-6.
2001: S Palmer; N Margot; H Gilbert; N Shaw; R Buckheit; M Miller
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
AIDS research and human retroviruses 2001;17(12):1167-73.
2001: L K Naeger; M Miller
Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
Current opinion in investigational drugs (London, England : 2000) 2001;2(3):335-9.
2000: Nancy S Shulman; Andrew R Zolopa; Douglas J Passaro; U Murlidharan; Dennis Israelski; Carol L Brosgart; M Miller; S Van Doren; Robert W Shafer; David A Katzenstein
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
Journal of acquired immune deficiency syndromes (1999) 2000;23(3):221-6.
2000: Koen K A Van Rompay; M Miller; Marta L Marthas; Nicolas A Margot; PJ Dailey; Don R Canfield; Ross P Tarara; Julie M Cherrington; NL Aguirre; Norbert Bischofberger; Niels C Pedersen
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Journal of virology 2000;74(4):1767-74.
1997: M Miller; Maria Warmerdam; Sharon Ferrell; R Benitez; Warner Greene
Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity.
Virology 1997;234(2):215-25.
1996: Romas Geleziunas; M Miller; Warner Greene
Unraveling the function of HIV type 1 Nef.
AIDS research and human retroviruses 1996;12(17):1579-82.
1996: M Miller; Warner Greene
Is the Nef protein of HIV-1 required for pathogenesis?
Trends in microbiology 1996;4(5):171-2; discussion 173.
1995: Mark A Goldsmith; M T Warmerdam; RE Atchison; M Miller; Warner Greene
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef.
Journal of virology 1995;69(7):4112-21.
1995: M Miller; M T Warmerdam; K A Page; Mark B Feinberg; Warner Greene
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.
Journal of virology 1995;69(1):579-84.
1994: M Miller; Mark B Feinberg; Warner Greene
The HIV-1 nef gene acts as a positive viral infectivity factor.
Trends in microbiology 1994;2(8):294-8.
1994: M Miller; M T Warmerdam; I Gaston; Warner Greene; Mark B Feinberg
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
The Journal of experimental medicine 1994;179(1):101-13.
1994: M Miller; R P Sheridan; S K Kearsley; Dennis J Underwood
Advances in automated docking applied to human immunodeficiency virus type 1 protease.
Methods in enzymology 1994;241():354-70.
1993: Norman L Letvin; M Miller; Ling Shen; Zheng W Chen; Y Yasutomi
Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.
Seminars in immunology 1993;5(3):215-23.
1992: Zheng W Chen; Ling Shen; M Miller; S H Ghim; Austin Hughes; Norman L Letvin
Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(12):4060-6.
1992: M Miller; S Gould-Fogerite; Ling Shen; Robert M Woods; Scott Koenig; Raphael J Mannino; Norman L Letvin
Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes.
The Journal of experimental medicine 1992;176(6):1739-44.
1992: H Yamamoto; D J Ringler; M Miller; Y Yasutomi; T Hasunuma; Norman L Letvin
Simian immunodeficiency virus-specific cytotoxic T lymphocytes are present in the AIDS-associated skin rash in rhesus monkeys.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(2):728-34.
1991: Keith A Reimann; G B Snyder; Laura V Chalifoux; B C Waite; M Miller; H Yamamoto; Olivier Spertini; Norman L Letvin
An activated CD8+ lymphocyte appears in lymph nodes of rhesus monkeys early after infection with simian immunodeficiency virus.
The Journal of clinical investigation 1991;88(4):1113-20.
1991: M Miller; H Yamamoto; Austin Hughes; David Ian Watkins; Norman L Letvin
Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(1):320-9.
1991: Ling Shen; Zheng W Chen; M Miller; V Stallard; Gail P Mazzara; D L Panicali; Norman L Letvin
Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.
Science (New York, N.Y.) 1991;252(5004):440-3.
1990: H Yamamoto; M Miller; David Ian Watkins; G B Snyder; N E Chase; Gail P Mazzara; Linda Gritz; D L Panicali; Norman L Letvin
Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysis.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(11):3740-6.
1990: H Yamamoto; M Miller; H Tsubota; David Ian Watkins; Gail P Mazzara; V Stallard; D L Panicali; A Aldovini; R A Young; Norman L Letvin
Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(9):3385-91.
1990: M Miller; Carol I Lord; V Stallard; Gail P Mazzara; Norman L Letvin
The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(1):122-8.